Electrotherapy System Market Scope And Analysis

Report Code : TIPHE100001378
Category : Life Sciences

No. of Pages : 150

Buy Now

Electrotherapy Systems Market Analysis Report 2021 to 2022

Buy Now

Electrotherapy Systems Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 4.21 Billion
Market Size by 2030	US$ 8.57 Billion
Global CAGR (2022 - 2030)	9.3%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Product Percutaneous Electrical Nerve Stimulation Spinal Cord Stimulation Transcutaneous Electrical Nerve Stimulation Micro-Current Therapy Interferential Current Therapy Electro-Acupuncture Pulsed Short Wave Diathermy Transcutaneous Spinal Electroanalgesia By Application Neuromuscular Dysfunction Pain Management Acute & Chronic Edema Sports Injury Treatment Iontophoresis Urine & Fecal Incontinence By End User Hospitals Clinics Long Term Care Centers Rehabilitation Centers
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	BTL DJO LLC Omron Healthcare Inc Abbott Boston Scientific Corporation Medtronic Nevro Corp Phoenix Healthcare Eme srl

Competitive Landscape and Key Companies:

The electrotherapy systems market report is focused on prominent players in the market. These include BTL, DJO LLC, Omron Healthcare Inc, Abbott, Boston Scientific Corporation, Medtronic, Nevro Corp, Phoenix Healthcare, Eme srl, and Pure Care. These companies focus on new technologies, upgrading existing products, and market expansions to meet the growing consumer demand worldwide. The electrotherapy systems market forecast can help stakeholders plan their growth strategies.

In January 2022, Medtronic plc, a global leader in healthcare technology, received approval from the US Food and Drug Administration (FDA) for its Intellis (rechargeable) and Vanta (recharge-free) neurostimulators for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). This new indication offers DPN patients access to Medtronic's industry-leading SCS portfolio of rechargeable and recharge-free solutions, including multiple programming options to personalize patient therapy, unrestricted MRI access, and unrivaled battery chemistry and performance, along with the Medtronic TYRX Neuro Absorbable Antibacterial Envelope.
In March 2021, the FDA approved an application by Medtronic plc for the revised commercial labeling for its Intellis platform with Differential Target Multiplexed (DTM) programming. The new labeling was meant to include study outcomes from a multicenter randomized control trial, mentioning superior back pain relief conferred by DTM SCS compared to conventional SCS.
In September 2020, Boston Scientific launched the WaveWriter Alpha portfolio of SCS systems in Europe. The four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs) launched in this portfolio offer greater personalization based on patient needs. The products also include rechargeable and non-rechargeable options, and access to waveforms covering multiple areas of pain.